🇺🇸 Bupivicaine + epinephrine in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 10
Most-reported reactions
- Acquired Diaphragmatic Eventration — 1 report (10%)
- Bronchial Disorder — 1 report (10%)
- Cardiac Disorder — 1 report (10%)
- Chest Pain — 1 report (10%)
- Dehydration — 1 report (10%)
- Dizziness — 1 report (10%)
- Dry Throat — 1 report (10%)
- Heart Rate Irregular — 1 report (10%)
- Hypoxia — 1 report (10%)
- Nerve Injury — 1 report (10%)
Other Anesthesia approved in United States
Frequently asked questions
Is Bupivicaine + epinephrine approved in United States?
Bupivicaine + epinephrine does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Bupivicaine + epinephrine in United States?
Rush University Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.